[ Back to EurekAlert! ] Public release date: 3-Dec-2012
[ | E-mail Share Share ]

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation

JCI early table of contents for Dec. 3, 2012

Lithium restores cognitive function in Down syndrome mice

Down syndrome is a neurodevelopmental disorder that is the leading cause of genetically defined intellectual disability. In the brain, Down syndrome results in alterations in the connections between neurons and a reduction in the development of new neurons (neurogenesis) that usually occurs during learning. In this issue of the Journal of Clinical Investigation, researchers led by Laura Gasparini at the Istituto Italiano di Tecnologia in Genova, Italy report that lithium, a drug commonly used for the treatment of mood disorders in humans, restores neurogenesis in the hippocampus, a part of the brain strongly associated with learning and memory. Lithium also significantly improved the performance of Down syndrome mice in tasks measuring contextual learning, spatial memory, and object discrimination. These results suggest that lithium-based therapies may help Down syndrome patients.

TITLE:
Lithium rescues synaptic plasticity and memory in Down syndrome mice

AUTHOR CONTACT:
Laura Gasparini
Istituto Italiano di Tecnologia, Genova, UNK, ITA
Phone: +3901071781519; Fax: +3901071781230; E-mail: laura.gasparini@iit.it

View this article at: http://www.jci.org/articles/view/64650?key=3cf4232a6447e03ab3e1


Stem cell-derived dopaminergic neurons rescue motor defects in Parkinsonian monkeys

Parkinson's disease is a degenerative disorder of the central nervous system that is characterized by tremors, rigidity, slowness of movement, and difficulty walking. It is caused by loss of the neurons that produce the neurotransmitter dopamine (known as dopaminergic neurons). One of the primary goals in Parkinson's disease research is to develop a replacement for dopaminergic neurons. In this issue of the Journal of Clinical Investigation, researchers led by Takuya Hayashi at the RIKEN Center for Molecular Imaging Science in Kobe, Japan, derived dopaminergic neurons from bone marrow stem cells in monkeys. The cells were retrieved during a standard bone marrow aspiration and then treated with growth factors that directed the stem cells to become dopaminergic neurons. The monkeys that donated the stem cells were treated with a chemical to induce Parkinson's disease and then received a transplant of the new dopaminergic neurons that had been derived from their own bone marrow stem cells. Monkeys that received the transplant showed significant improvement in motor defects. This study demonstrates that dopaminergic neurons derived from adult bone marrow stem cells can be safely used to improve motor function in Parkinson's disease in monkeys.

TITLE:
Autologous mesenchymal stem cell–derived dopaminergic neurons function in parkinsonian macaques

AUTHOR CONTACT:
Takuya Hayashi
RIKEN Center for Molecular Imaging Science, Kobe, JPN
Phone: +81-78-304-7121; E-mail: takuya.hayashi@riken.jp

View this article at: http://www.jci.org/articles/view/62516?key=7d6d0d8317b927dfb1d0


Researchers inhibit plaque formation in a mouse model of Alzheimer's disease

Alzheimer's disease is characterized by the accumulation of protein plaques in the brain. The plaques are generated by BACE1-mediated cleavage of the β-amyloid precursor protein. In this issue of the Journal of Clinical Investigation, researchers led by Weihong Song at the University of British Columbia, demonstrate that the cellular signaling protein GSK3β promoted BACE1 expression and increased cleavage of the β-amyloid precursor protein. Inhibition of GSK3β blocked the formation of plaques in the brains of mice with a genetically engineered form of Alzheimer's disease and improved their performance in memory tasks. These results suggest that drugs targeting GSK3β might be effective in treating Alzheimer's disease.

TITLE:
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes

AUTHOR CONTACT:
Weihong Song
The University of British Columbia, Vancouver, BC, CAN
Phone: 604-822-8019; E-mail: weihong@exchange.ubc.ca

View this article at: http://www.jci.org/articles/view/64516?key=e6acfc0c1540a1067a3e


Tempering inflammation to treat the flu

Infection with the influenza virus induces an immune response to fight the virus; however, this natural defense sometimes results in excessive inflammation that can damage the lungs. In this issue of the Journal of Clinical Investigation, researchers led by Béatrice Riteau at the University of Lyon in Lyon, France, found that mice infected with influenza A had increased PAR1 activity, a protein that attracts inflammatory cells to the site of infection. To determine if PAR1 plays a role in the damaging inflammation caused by the influenza virus, Riteau and colleagues generated mice that lacked PAR1 or treated them with a drug that blocks PAR1 activity. Interestingly, both groups of mice were protected from influenza virus A infection. This study suggests that drugs that block PAR1 activity might be useful in treating influenza.

TITLE:
PAR1 contributes to influenza A virus pathogenicity in mice

AUTHOR CONTACT:
Béatrice Riteau
Universite de Lyon, INRA (Institut National de la Recherche Agronomique), Lyon, FRA
Phone: 33(4)78771008; E-mail: beatrice.riteau@univ-lyon1.fr

View this article at: http://www.jci.org/articles/view/61667?key=f7e425306056041665a0


Lysosomal disruption targets acute myeloid leukemia cells

Acute myeloid leukemia (AML), a cancer that originates in the bone marrow, is the most common form of leukemia in adults. The disease is very difficult to treat and many patients experience relapses that are likely caused by the presence of chemotherapy-resistant leukemia initiating cells. In this issue of the Journal of Clinical Investigation, researchers led by Mahadeo Sukhai and Aaron Schimmer at the Princess Margaret Hospital in Toronto, Ontario, screened 100 common drugs to identify agents that could kill leukemia cells. They found that the malaria drug mefloquine selectively killed human AML cells and leukemia initiating cells by targeting a portion of the cell known as the lysosome. These results suggest that drugs which target the lysosome maybe useful in treating AML.

TITLE:
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors

AUTHOR CONTACT:
Mahadeo Sukhai
University Health Network, Toronto, ON, CAN
Phone: 416-946-4501 x 3498; E-mail: m.sukhai@utoronto.ca

View this article at: http://www.jci.org/articles/view/64180?key=0c7313028208f101619b


Researchers identify key gene transcription changes in acute myeloid leukemia

Abnormal gene transcription contributes to the pathogenesis of many cancers. CDX2 is a transcriptional regulatory protein that is expressed in the leukemic cells of 90% of acute myeloid leukemia (AML) patients, but the genes that it targets have not been defined. In this issue of the Journal of Clinical Investigation, researchers led by Stefan Fröhling at the German Cancer Research Center in Heidelberg, Germany, report that CDX2-mediated leukemogenesis is dependent on the protein KLF4. Interestingly, the effects of CDX2 on KLF4 are tissue-dependent. CDX2 repressed the expression of KLF4 in AML, but not in other forms of cancer. Additionally, Fröhling and colleagues identified signaling pathways that reactivate expression of KLF4, countering the effects of CDX2. These studies suggest that regulation of KLF4 expression could provide a new therapeutic target in the treatment of AML.

TITLE:
Leukemogenesis by CDX2 involves KLF4 repression and deregulated PPARγ signaling

AUTHOR CONTACT:
Stefan Fröhling
German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, UNK, DEU
Phone: +49-6221-42-1633; Fax: +49-6221-42-1610; E-mail: stefan.froehling@nct-heidelberg.de

View this article at: http://www.jci.org/articles/view/64745?key=98dd7bf0b61b8321a0e3


Gene transcription mediates the production of inflammatory factors during sepsis

Septic shock is a severe systemic infection that frequently results in multiple organ failure. The bacteria that cause the infection drive a sustained inflammatory response that can cause further damage. TNFα is an inflammatory factor that is induced in the liver and is a key determinant of liver failure during septic shock. In this issue of the Journal of Clinical Investigation, researchers led by Guadalupe Sabio at the Centro Nacional de Investigaciones Cardiovasculares Carlos III in Madrid, Spain, examined the regulation of TNFα gene transcription in a mouse model of bacterially-induced liver inflammation. They found that a stress response pathway regulated the activity of the protein that mediates TNFα transcription. These data demonstrate that inflammatory responses can be mediated by gene transcription and suggest that these factors are potential targets for the treatment of liver disease.

TITLE:
Eukaryotic elongation factor 2 controls TNF-α translation in LPS-induced hepatitis

AUTHOR CONTACT:
Guadalupe Sabio
Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, UNK, ESP
Phone: 0034644204989; E-mail: gsabio@cnic.es

View this article at: http://www.jci.org/articles/view/65124?key=410a849a38b1d7a0809f

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.